Identification and structural characterization of febuxostat metabolites in rat serum and urine samples using UHPLC-QTOF/MS.
Liping ZhouHexiang LiuZhongyong XuSu GuanLei ZhangPublished in: Biomedical chromatography : BMC (2019)
Febuxostat is a novel nonpurine type of highly selective xanthine oxidoreductase inhibitor. A rapid and sensitive ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry method for simultaneous separation and determination of febuxostat and its metabolites in rat serum and urine was developed at various time points after oral administration to the rats. The febuxostat metabolites were predicted by biotransformation software and transformed to a personal compound database to quickly determine the possible metabolites from the MS1 data. The possibility of the MS/MS fragmentation was calculated by the Molecular Structure Correlator software. As a result, five phase I and two phase II metabolites in rat serum, and seven phase I and three phase II metabolites in rat urine were identified, of which four metabolites (M2, M5, M6, M7) have not been reported before. The metabolite toxicities are predicted, and the results are helpful for the design of new xanthine oxidoreductase inhibitors.
Keyphrases
- ms ms
- phase ii
- ultra high performance liquid chromatography
- liquid chromatography tandem mass spectrometry
- clinical trial
- oxidative stress
- open label
- tandem mass spectrometry
- mass spectrometry
- high performance liquid chromatography
- simultaneous determination
- uric acid
- phase iii
- placebo controlled
- big data
- high resolution
- electronic health record
- data analysis